Nurix Therapeutics, a biopharma company specializing in targeted protein degradation, provided an update at the Wells Fargo Healthcare Conference. Their lead drug, a BTK degrader, is in pivotal trials for chronic lymphocytic leukemia (CLL) and advancing to Phase II for chronic spontaneous urticaria and multiple sclerosis. Nurix also highlighted partnerships with Roche for Bexdeg and discovery collaborations with Gilead, Sanofi, and Pfizer, focusing on other protein degraders like STAT6 and IRAK4. These developments position Nurix as a multi-therapeutic player with promising pipeline progress and strong industry collaborations.
RH is set to report Q2 2026 earnings facing challenges from a weak housing market and international expansion expenses. Analysts expect earnings per share to fall significantly to between $0.38 and $0.46, down from $2.93 last year, despite a slight r...
Chewy reported Q2 results largely in line with expectations, with net sales up 7.3% to $3.33 billion and adjusted earnings matching forecasts at $0.36 per share. However, shares fell 10.8% due to concerns about slowing organic growth, cautious consum...
Macy's reported Q1 earnings per share of $0.40, exceeding the $0.37 estimate, with revenue of $4.87 billion beating expectations. Growth was driven by strong sales in Bloomingdale's, Bluemercury, and Macy's stores. The company raised its full-year ne...
Tyson Foods faces operational challenges, especially in its beef segment, leading Piper Sandler to cut its price target from $78 to $66. The company lowered its 2026 revenue growth forecast to 1.5%-2% and expects a beef segment operating loss between...
Descartes Systems Group is set to release its Q2 2027 earnings with analysts expecting $0.57 EPS and $197.54 million revenue. The company recently acquired Extensiv for $120 million, enhancing its warehouse and fulfillment solutions for e-commerce an...
